within Pharmacolibrary.Drugs.ATC.H;

model H01CC02
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.6666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 3 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.012,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0036,
    k12             = 1.2,
    k21             = 1.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>H01CC02</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Cetrorelix is a synthetic decapeptide gonadotropin-releasing hormone (GnRH) antagonist used primarily in assisted reproduction to prevent premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation. It is approved in many countries for use in in vitro fertilization and related protocols.</p><h4>Pharmacokinetics</h4><p>Healthy premenopausal women; pharmacokinetics after a single subcutaneous administration.</p><h4>References</h4><ol><li><p>Erb, K, et al., &amp; Hermann, R (2001). Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women. <i>Fertility and sterility</i> 75(2) 316–323. DOI:<a href=&quot;https://doi.org/10.1016/s0015-0282(00)01702-7&quot;>10.1016/s0015-0282(00)01702-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11172833/&quot;>https://pubmed.ncbi.nlm.nih.gov/11172833</a></p></li><li><p>Erb, K, et al., &amp; Hermann, R (2002). Novel formulations of cetrorelix acetate in healthy men: pharmacodynamic effects and noncompartmental pharmacokinetics. <i>Journal of clinical pharmacology</i> 42(9) 995–1001. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12211225/&quot;>https://pubmed.ncbi.nlm.nih.gov/12211225</a></p></li><li><p>Nagaraja, NV, et al., &amp; Derendorf, H (2000). Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women. <i>Clinical pharmacology and therapeutics</i> 68(6) 617–625. DOI:<a href=&quot;https://doi.org/10.1067/mcp.2000.111481&quot;>10.1067/mcp.2000.111481</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11180022/&quot;>https://pubmed.ncbi.nlm.nih.gov/11180022</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end H01CC02;
